Because Anson is a minority/woman-owned business, we are particularly excited to work with clients who continue to research and develop products that target diseases disproportionately affecting those specific subpopulations.
Indianapolis, IN (Vocus) February 27, 2010
The Anson Group hopes to draw more attention to the urgent need of finding more treatments for rare diseases by partnering with the National Organization for Rare Diseases (NORD) to sponsor Rare Disease Day in the United States, February 28th, 2010.
Anson Group, a regulatory consulting company, has had the privilege of providing regulatory support for multiple products that are indicated for the treatment of a number of rare diseases. Anson has aided clients in obtaining Orphan Drug status (for pharmaceutical entities) and Humanitarian Use Designations (for medical devices) for products intended to treat diseases like gastrointestinal stromal tumor (GIST), mastocytosis and multiple myeloma, as well as multiple sclerosis and amyotrophic lateral sclerosis (ALS). Most recently, Anson Group helped prepare materials for an FDA Advisory Committee meeting regarding a new treatment for Niemann-Pick Type C (NPC) disease.
Anson supports the need for continued research and innovation in rare diseases. As scientists continue to work to evolve treatments to target more specific disease pathways, subpopulations and rare diseases will become increasingly important in the understanding and practice of true personalized medicine. Anson Group will continue to invest in building our expertise in regulatory requirements for these products in order to expand our role in ensuring promising treatments reach the market for those who suffer from rare conditions.
“Anson is proud of our 15 year history of helping all of our clients get their medical technologies to market as quickly as possible and in compliance with the applicable regulations; that said, no project we work on is more gratifying from a personal perspective than working on a product that might only apply to a small percentage of people but enables them to have a better quality of life,” states Gerry Richardson, CEO of Anson Group. “Because Anson is a minority/woman-owned business, we are particularly excited to work with clients who continue to research and develop products that target diseases disproportionately affecting those specific subpopulations.”
About Anson Group
Headquartered in Carmel Indiana, Anson Group is a minority-owned independent consulting organization with over 15 years experience as a leading provider of services and strategies for FDA product approval and compliance for devices, drugs, biologics, and combination products. Anson Group’s team of experienced industry experts tailors both enterprise strategies and clearly-defined action plans that help its clients address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.